Compare Organon & Co. Common Stock (OGN) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Raymond James Financial, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B). The key difference: Raymond James Financial, Inc. is far larger — about 8.4× Organon & Co. Common Stock's market cap, and Raymond James Financial, Inc. pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Raymond James Financial, Inc. for 75 Days on average.
| OGN | RJF | |
|---|---|---|
Market Cap | $3.61B | $30.15B |
Volume | 1,808,049 | 980,106 |
Sector | Health | Financials |
52-Week High | $13.81 | $181.18 |
52-Week Low | $5.70 | $140.89 |
Typical Hold Time | 0 Days | 75 Days |
Enterprise Value | $11.03B | $24.02B |
Dividend Yield | 0.58% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Raymond James Financial (RJF) trades at $156.78, down 1.18% with bearish technical indicators but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.14 exceeding expectations. Revenue growth has been steady from $10.9B in 2022 to $13.8B in 2025, with net income margins above 15%. Recent leadership transitions and PGA TOUR sponsorship highlight strategic developments.
The outlook remains positive with a $178.50 consensus price target representing 14% upside potential. Analyst consensus leans Hold (55.56%) with no Sell ratings, indicating cautious optimism. Key risks include volatile cash flows from investing activities and brokerage market sensitivity. The company's strong profitability metrics and institutional accumulation support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
